By Katherine Hamilton

Galapagos is exploring strategic alternatives for its cell therapy business, including a potential divestiture.

The Belgian biotechnology company said Wednesday it has received a limited number of non-binding offers, mostly from financial investors, to acquire the cell therapy business. Parties interested in acquiring the business have had access to a comprehensive data room and confidential presentations on the cell therapy business.

Galapagos' board and management are now working with the potential bidders to finalize due diligence and see if they can raise the necessary funding. The deadline for potential bidders to put forward fully financed binding offers will happen in the coming weeks, Galapagos said.

The board expects to make a decision about which strategic alternative it will choose after it receives those binding offers, if there are any. Galapagos will announce its decision no later than Nov. 5, when it plans to release its third-quarter results, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

October 01, 2025 16:27 ET (20:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.